Last reviewed · How we verify
Capecitabine oral administration
Capecitabine oral administration is a Small molecule drug developed by Akamis Bio. It is currently in Phase 1 development.
At a glance
| Generic name | Capecitabine oral administration |
|---|---|
| Sponsor | Akamis Bio |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Anaemia
- Diarrhoea
- Decreased appetite
- Vomiting
- Fatigue
- Neutropenia
- Neutrophil count decreased
- Weight decreased
- Constipation
- Palmar-plantar erythrodysaesthesia syndrome
- DIARRHOEA
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (PHASE1, PHASE2)
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) (PHASE3)
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (PHASE3)
- Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy (NA)
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (PHASE2, PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine oral administration CI brief — competitive landscape report
- Capecitabine oral administration updates RSS · CI watch RSS
- Akamis Bio portfolio CI
Frequently asked questions about Capecitabine oral administration
What is Capecitabine oral administration?
Capecitabine oral administration is a Small molecule drug developed by Akamis Bio.
Who makes Capecitabine oral administration?
Capecitabine oral administration is developed by Akamis Bio (see full Akamis Bio pipeline at /company/akamis-bio).
What development phase is Capecitabine oral administration in?
Capecitabine oral administration is in Phase 1.
What are the side effects of Capecitabine oral administration?
Common side effects of Capecitabine oral administration include Nausea, Anaemia, Diarrhoea, Decreased appetite, Vomiting, Fatigue.
Related
- Manufacturer: Akamis Bio — full pipeline
- Compare: Capecitabine oral administration vs similar drugs
- Pricing: Capecitabine oral administration cost, discount & access